Tested in a laboratory, not in a marketing meeting.

The measurements

Before and after, as recorded.

T₀ was measured on cleansed skin before the first application. T₁ was measured on the same individually marked areas of the face after four weeks of use. Both readings were taken in the same air conditioned room at 20 to 25°C and 40 to 60% relative humidity.

Measurement uncertainty for all three parameters was 3%. Under the laboratory's own rule a claim is confirmed only where improvement is seen in the majority of subjects, at least 6 of 10, and only where the change exceeds that uncertainty. All three parameters cleared both conditions. Instruments supplied by Courage & Khazaka.

Skin compatibility

Twenty volunteers. Forty eight hours under occlusion. No reactions.

Créma was applied under occlusive chambers to the back of 20 volunteers aged 25 to 59 and left in place for 48 hours. Skin was assessed against the International Contact Dermatitis Research Group scale 15 minutes after the patches were removed, and again at 72 hours.

No positive contact allergy or irritant reaction was observed in any subject at either reading. The laboratory concluded that the product meets the requirements of the Skin Compatibility Test and may be assessed as non irritant. The report is signed by M.D. Marta Taube.

The laboratory notes that this opinion does not extend to individuals who are allergic to any single component of the formula.

The rulebook it was built to

Europe and the United States do not hold skincare to the same bar.

Créma is formulated, manufactured and tested inside the European framework. That is not a marketing preference. It is a different legal standard, and it changes what a product has to prove before anyone is allowed to sell it.

Both sides of this table moved recently. The Modernization of Cosmetics Regulation Act, in force since 2023, gave the FDA registration, listing, safety substantiation, adverse event reporting and recall powers it did not previously have, and finalised manufacturing rules are expected. American oversight is materially stronger than it was. On the measures above, the European framework still sets the higher bar.

Where Créma sits

We chose the stricter rulebook, then paid for the testing to prove it.

The botanicals, the formulation laboratory and the manufacturing are all in Greece, so Créma is made inside that European framework rather than merely sold into it. Meeting the rulebook is the baseline. It is not evidence.

The evidence is the four reports on this page. They were commissioned from an independent laboratory and scoped explicitly to those European rules. The instrumental study and the patch test both name EC 1223/2009 and the Cosmetics Europe efficacy and skin compatibility guidelines in their terms of reference. The efficacy claims were assessed against EC 655/2013, the common criteria that governs what a cosmetic brand is permitted to say. The microbiological analysis was run against the limits set in the same regulation, under an accredited scope.

That is the whole argument. A stricter standard, an independent laboratory, and the signed reports published here so you can check the work rather than take our word for it.